eloralintide (LY3841136) / Eli Lilly - LARVOL DELTA

A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity (clinicaltrials.gov) - P1 | N=204 | Active, not recruiting | Sponsor: Eli Lilly and Company | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight (clinicaltrials.gov) - P1 | N=30 | Completed | Sponsor: Eli Lilly and Company | Active, not recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. (PubMed, Lancet) - P2 | "Eloralintide produced clinically meaningful, dose-dependent reductions in bodyweight over 48 weeks and was generally well tolerated, supporting eloralintide's potential use for obesity treatment."

Journal • P2 data • Diabetes • Fatigue • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Scientific Basis of Amylin Agonism in the Treatment of Obesity and Weight Management (OBESITY WEEK 2025) - "Background: This presentation will provide the scientific background of amylin as well as introduce eloralintide, a selective long-acting, once-weekly amylin receptor agonist under development for weight management... Hence, amylin seems to affect caloric intake by various modes of action."

Genetic Disorders • Metabolic Disorders • Obesity • LEP

Eloralintide Phase 2 in Overweight/Obesity: Safety Evaluation - followed by Discussion and Q&A (OBESITY WEEK 2025) - "Safety and tolerability of eloralintide will be evaluated in this presentation."

Clinical • P2 data • Cardiovascular • Fatigue • Gastrointestinal Disorder • Genetic Disorders • Hepatology • Infectious Disease • Novel Coronavirus Disease • Obesity • Psychiatry • Suicidal Ideation

Eloralintide Phase 2 in Overweight/Obesity: Design and Study Population (OBESITY WEEK 2025) - "This presentation will also detail the demographics and clinical characteristics of the trial population."

Clinical • P2 data • Genetic Disorders • Obesity

Eloralintide Phase 2 in Overweight/Obesity: Weight Loss Efficacy (OBESITY WEEK 2025) - "The primary estimand of interest when comparing the efficacy of eloralintide treatment with placebo was an efficacy estimand, representing the efficacy of eloralintide relative to placebo for all participants prior to the discontinuation of the study intervention. A treatment estimand was also used, representing the efficacy eloralintide versus placebo irrespective of study intervention."

Clinical • P2 data • Genetic Disorders • Obesity

Eloralintide, a Selective Amylin Analog, Improves Insulin Sensitivity in Diet-induced Obese Rats (OBESITY WEEK 2025) - "Herein, we present eloralintide, a selective amylin analog, that we previously showed had potent effects on weight loss efficacy and body composition changes (fat and lean mass ratios) in DIO rats compared to the non-selective amylin, cagrilintide. Eloralintide, a selective amylin receptor agonist, demonstrated weight loss primarily driven by fat mass reductions, and weight-independent improvements in glucose homeostasis mediated by insulin sensitivity in DIO rats after chronic administration. These findings support clinical investigation of eloralintide as an obesity management medication."

Preclinical • Genetic Disorders • Obesity

Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight (PRNewswire) - "At 48 weeks, all treatment arms of eloralintide met the primary endpoint, demonstrating superior mean weight reductions from 9.5% to 20.1% compared to 0.4% with placebo using the efficacy estimand. Results from the trial were presented at ObesityWeek 2025 and simultaneously published in The Lancet...Treatment with eloralintide was also associated with improvements across cardiometabolic risk factors including waist circumference, blood pressure, lipid profiles, glycemic control and markers of inflammation...The most common adverse events were mild to moderate gastrointestinal symptoms and fatigue, which were seen more frequently in the higher dose arms....Lilly plans to initiate Phase 3 clinical studies of eloralintide as a monotherapy for the treatment of obesity by the end of this year and is evaluating its use as a complementary treatment to incretin therapy."

New P3 trial • P2 data • Obesity

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes (clinicaltrials.gov) - P2 | N=200 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes (clinicaltrials.gov) - P2 | N=200 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P2 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. (PubMed, Mol Metab) - P1 | "Once-weekly dosing with eloralintide, an AMY1R-selective agonist, may offer a promising new therapeutic with favorable gastrointestinal tolerability for the treatment of obesity."

Journal • Genetic Disorders • Obesity

A Study of LY3841136 in Overweight and Obese Participants (clinicaltrials.gov) - P1 | N=96 | Completed | Sponsor: Eli Lilly and Company | Active, not recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight (clinicaltrials.gov) - P2 | N=1217 | Recruiting | Sponsor: Eli Lilly and Company | Trial primary completion date: Sep 2026 ➔ Jun 2026

Trial primary completion date • Genetic Disorders • Obesity

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes (clinicaltrials.gov) - P2 | N=350 | Active, not recruiting | Sponsor: Eli Lilly and Company | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A phase 1, double blind, multiple ascending dose study of eloralintide in Japanese participants with overweight or obesity (EASD 2025) - P1 | "In Japanese participants with overweight or obesity, the long-acting selective amylin receptor agonist eloralintide was safe and well tolerated, and with clinically meaningful body weight loss. Pharmacokinetics support once weekly subcutaneous dosing. Eloralintide may be an important option for weight management in people with overweight or obesity, with and without diabetes."

Clinical • Late-breaking abstract • P1 data • Diabetes • Metabolic Disorders • Obesity

Eloralintide (LY3841136), a selective amylin analog, lowered body weight with improved quality of weight loss and GI tolerability in rats compared to cagrilintide (EASD 2025) - "Eloralintide demonstrated preclinical improvements in efficacy, GI tolerability, and quality of weight loss compared to the non-selective amylin analog cagrilintide. These findings support clinical investigation of eloralintide as a weight loss therapeutic."

Preclinical • Metabolic Disorders

Eloralintide, a selective, long-acting amylin receptor agonist for obesity: phase 1 proof of concept (EASD 2025) - P1 | "Unlike other amylin agonist molecules (e.g., Cagrilintide), it is designed to have minimal calcitonin activity in the clinic.Materials and This 12 week (wk) phase 1, randomized, placebo-controlled, double-blind study evaluated safety, tolerability, PK, and PD of QW subcutaneous Elora in participants with obesity or overweight. At 12 wks, Elora QW was well tolerated with minimal GI AEs and resulted in meaningful weight loss. An ongoing Phase 2 study will further explore efficacy and tolerability of Elora."

P1 data • Metabolic Disorders • Obesity

A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight (clinicaltrials.gov) - P2 | N=263 | Completed | Sponsor: Eli Lilly and Company | Active, not recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight (clinicaltrials.gov) - P1 | N=36 | Active, not recruiting | Sponsor: Eli Lilly and Company | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight (clinicaltrials.gov) - P2 | N=1217 | Recruiting | Sponsor: Eli Lilly and Company | Trial primary completion date: Jun 2026 ➔ Sep 2026

Trial primary completion date • Genetic Disorders • Obesity

Eloralintide, a Selective, Long-Acting Amylin Receptor Agonist for Obesity—Phase 1 Proof of Concept (ADA 2025) - P2 | "Unlike other amylin agonist molecules (e.g. Cagrilintide), it is designed to have minimal calcitonin activity in the clinic. The 12 wk phase 1, randomized, placebo (PBO) controlled, double blind study evaluated safety, tolerability, PK, and PD of QW SC Elora in participants with obesity or overweight. At 12 wks, Elora QW was well tolerated with minimal GI AEs and resulted in meaningful weight loss. A phase 2 study (NCT06230523) will further explore safety and efficacy of Elora."

P1 data • Metabolic Disorders • Obesity

Eloralintide (LY3841136), a Selective Amylin Mimetic, Lowered Body Weight with Improved Quality of Weight Loss and GI Tolerability in Rats Compared with Cagrilintide (ADA 2025) - "Eloralintide demonstrated preclinical improvements in efficacy, GI tolerability, and quality of weight loss compared to the non-selective amylin analog cagrilintide. These findings support clinical investigation of eloralintide as a weight loss therapeutic."

Preclinical • Metabolic Disorders

The Amylin Receptor Selective Agonist NN1213 Reduces Food Intake and Body Weight in Rats without Decreasing Calcium Plasma Levels (ADA 2025) - "Cagrilintide and eloralintide are both AMYR and CTR agonists whereas NN1213 is a selective AMYRs agonist that also decreases body weight in rats."

Preclinical • Metabolic Disorders • Obesity

Lilly’s experimental obesity drug shows promise in early study (Hastings Tribune) - P1 | N=188 | NCT06916065 | Sponsor: Eli Lilly and Company | "The drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months...The study enrolled 100 patients who were given different doses of the experimental drug or a placebo for 12 weeks. Weight loss ranged from 2.6% to 11.3%, according to the abstract. Gastrointestinal side effects were relatively minimal, with about 10% of patients experiencing diarrhea and 8% vomiting."

P1 data • Obesity